Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
Awareness campaign includes educational resources and testing information for individuals with suspected NPC. CELEBRATION, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced, on Rare Disease Day, the launch of a new disease state awareness campaign, ' Learn NPC, Read Between the Signs ,' to highlight the need for early recognition and diagnosis due to the heterogeneity of symptoms related to Niemann-Pick disease type C (NPC). NPC is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder with varying age of onset and symptom presentation, often
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.MarketBeat
- Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..MarketBeat
- Zevra Reports Full Year 2024 and Fourth Quarter Financial Results [Yahoo! Finance]Yahoo! Finance
- Zevra Reports Full Year 2024 and Fourth Quarter Financial ResultsGlobeNewswire
ZVRA
Earnings
- 3/11/25 - Miss
ZVRA
Sec Filings
- 3/13/25 - Form S-8
- 3/12/25 - Form 10-K
- 3/11/25 - Form 8-K
- ZVRA's page on the SEC website